BNP Paribas Financial Markets Increases Position in ChromaDex Co. (NASDAQ:CDXC)

BNP Paribas Financial Markets increased its position in shares of ChromaDex Co. (NASDAQ:CDXC) by 1,885.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 73,272 shares of the company’s stock after acquiring an additional 69,582 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.10% of ChromaDex worth $267,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex during the second quarter worth $31,000. Merriman Wealth Management LLC purchased a new position in ChromaDex during the second quarter worth about $32,000. FMR LLC purchased a new stake in ChromaDex in the 3rd quarter valued at about $55,000. Marshall Wace LLP acquired a new position in shares of ChromaDex during the 2nd quarter valued at about $56,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex in the third quarter worth approximately $61,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 9.64% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CDXC shares. HC Wainwright increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 9th. Finally, Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

ChromaDex Trading Down 4.1 %

Shares of CDXC stock opened at $6.12 on Monday. The company has a market cap of $467.45 million, a PE ratio of 612.61 and a beta of 2.16. The company’s fifty day simple moving average is $5.66 and its 200-day simple moving average is $3.99. ChromaDex Co. has a 52 week low of $1.32 and a 52 week high of $7.97.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same period last year, the company posted ($0.01) earnings per share. Equities research analysts expect that ChromaDex Co. will post 0.04 EPS for the current fiscal year.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.